Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina.

Autor: Espinola, Natalia1 nespinola@iecs.org.ar, Silvestrini, Constanza1, Colaci, Carla1, Sugg, Daniela2,3,4,5, Rojas-Roque, Carlos1,6, Coelli, Jesica1, Augustovski, Federico1
Zdroj: PharmacoEconomics - Open. Sep2024, Vol. 8 Issue 5, p727-738. 12p.
Databáze: Business Source Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje